Publication:
Relationship between pet/ct response and survival in patients with non-small-cell lung cancer treated with definitive chemoradiotherapy

dc.contributor.authorSarıhan, Süreyya
dc.contributor.authorBilgin, Gökçe Beige
dc.contributor.authorSığırlı, Deniz
dc.contributor.buuauthorSARIHAN, SÜREYYA
dc.contributor.buuauthorBilgin, Gökçe Beige
dc.contributor.buuauthorSIĞIRLI, DENİZ
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nükleer Tıp Anabilim Dalı
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı
dc.contributor.orcid0000-0003-4816-5798
dc.contributor.researcheridAAH-4970-2021
dc.contributor.researcheridEMG-1218-2022
dc.contributor.researcheridAAA-7472-2021
dc.date.accessioned2024-06-24T10:58:38Z
dc.date.available2024-06-24T10:58:38Z
dc.date.issued2021-01-01
dc.description.abstractWe aimed to evaluate the relationship between PET/CT response and survival in patients with non-small cell lung cancer (NSCLC) treated with curative chemoradiotherapy. Between January and December 2012, 51 patients were treated. The median age was 61 (29-79) and the M/F ratio was 46/5. Eighty two percent of the cases were stage III and 53% were squamous cell carcinoma. Median 6300 cGy (4860-7525) radiotherapy delivered and 92% of patients received chemotherapy. The median follow-up was 27 months (7-96 months) in November 2019. The objective response was 71% with CT at 1 month and 76% with PET/CT at 3 months. There was a significant correlation between response-1 and response-3 (p< 0.001). Tumor SUVmean3 < 2.81, SUVmax change >= 70% was associated with response-1 (p< 0.05). The median and 5-year overall (OS) and progression-free (PFS) survival rates were 54 months, 40% and 35 months, 38%, respectively. In Cox model, for each 1 unit increase, SUVmeanbase (HR: 1.18, 95% CI: 1.01-1.38) and SUVmean3 (HR: 2.65, 95% CI: 1.24-5.66) were found unfavorable factors for OS, whereas SUVmean3 (HR: 2.01, 95% CI: 1.02-3.93) was also found to be a poor prognostic factor for PFS. PET/CT parameters can be used as useful markers for prognosis in patients with NSCLC undergoing curative chemoradiotherapy. It is believed that early assessment during and after treatment can be advantageous in terms of treatment modification.
dc.identifier.doi10.4999/uhod.214343
dc.identifier.endpage18
dc.identifier.issn1306-133X
dc.identifier.issue1
dc.identifier.startpage8
dc.identifier.urihttps://doi.org/10.4999/uhod.214343
dc.identifier.urihttps://www.uhod.org/pdf/PDF_866.pdf
dc.identifier.urihttps://hdl.handle.net/11452/42281
dc.identifier.volume31
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherAkad Doktorlar Yayınevi
dc.relation.journalUluslararası Hematoloji-onkoloji Dergisi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPositron-emission-tomography
dc.subjectMetabolic tumor volume
dc.subjectFdg-pet
dc.subjectNeoadjuvant chemotherapy
dc.subjectChemoradiation therapy
dc.subjectComputed-tomography
dc.subjectF-18-fdg pet
dc.subjectConcurrent chemoradiation
dc.subjectPathological response
dc.subjectRadical radiotherapy
dc.subjectNon-small cell lung cancer
dc.subjectDefinitive chemo-rt
dc.subjectPet/ct response
dc.subjectSurvival
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectOncology
dc.titleRelationship between pet/ct response and survival in patients with non-small-cell lung cancer treated with definitive chemoradiotherapy
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication07b16629-e65c-40b0-b11d-825ad7943570
relation.isAuthorOfPublicationf8b7b771-12ea-4f9a-889d-25079d8c862d
relation.isAuthorOfPublication.latestForDiscovery07b16629-e65c-40b0-b11d-825ad7943570

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Sarıhan_vd_2021.pdf
Size:
320.01 KB
Format:
Adobe Portable Document Format

Collections